Lilly Zyprexa IM filing update
Executive Summary
Lilly's Zyprexa (olanzapine) intramuscular NDA filing may be delayed until early 2002, U.S. Operations President Gino Santini indicates during CIBC's healthcare analysts conference in New York City Oct. 5. Lilly had earlier predicted the IM antipsychotic would be launched in the fourth quarter with the sepsis drug Xigris (drotrecogin alfa) (1"The Pink Sheet" Oct. 8, p. 27)...